Zhang Ying, Ding Shaoxue, Li Caifeng, Wang Yifeng, Chen Zhe, Wang Zhiqiang
Intensive Care Unit, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China.
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China.
Exp Ther Med. 2017 Oct;14(4):2863-2868. doi: 10.3892/etm.2017.4891. Epub 2017 Aug 7.
Acute respiratory distress syndrome (ARDS) is a serious complication of acute lung injury. Severe systemic inflammation is the main cause of multiple organ dysfunction and high mortality. Removal of reactive oxygen species by anti-oxidants has been applied in clinical practice. N-acetylcysteine (NAC) is the most commonly used anti-oxidant. However, the benefit of anti-oxidant therapy was not consistently demonstrated by previous studies. In the present study, a meta-analysis was performed to evaluate the effects of NAC for adult patients with ARDS. The PubMed, Cochrane and EMBASE databases were searched to retrieve all of the available randomized controlled trials (RCTs) published until October 2015. Quality evaluation of included studies was performed according to the modified Jadad scale score. The Cochrane Collaboration Review Manager 5.3 software was used to perform the meta-analysis. Five RCTs comprising 183 patients were found to be eligible for inclusion in the meta-analysis. Pooled analysis showed that NAC did not contribute to reduce short-term mortality [risk ratio (RR)=0.73; 95% confidence interval (CI): 0.50-1.07; P=0.10] or 30-day mortality (RR=0.72; 95% CI: 0.44-1.19; P=0.20) when compared with those in the control group. However, duration of intensive care unit (ICU) stay in the NAC group was shortened [weighted mean difference (WMD), -4.56; 95% CI: (-7.32 to -1.80); P=0.001]. There was no significant difference in the ratio of partial arterial oxygen pressure to the fraction of inspired oxygen between the two groups [WMD, 54.34; 95% CI: (-30.50 to 139.17); P=0.21]. No severe adverse reactions were observed in the patients included. Although the duration of ICU stay was shortened, the clinical benefits of NAC were limited for ARDS based on the present meta-analysis. As the number of included trials and patients was small, additional trials are required to provide sufficient evidence for the efficacy of NAC in ARDS.
急性呼吸窘迫综合征(ARDS)是急性肺损伤的一种严重并发症。严重的全身炎症是多器官功能障碍和高死亡率的主要原因。抗氧化剂清除活性氧已应用于临床实践。N-乙酰半胱氨酸(NAC)是最常用的抗氧化剂。然而,先前的研究并未一致证明抗氧化剂治疗的益处。在本研究中,进行了一项荟萃分析以评估NAC对成年ARDS患者的影响。检索了PubMed、Cochrane和EMBASE数据库,以获取截至2015年10月发表的所有可用随机对照试验(RCT)。根据改良的Jadad量表评分对纳入研究进行质量评估。使用Cochrane协作网Review Manager 5.3软件进行荟萃分析。发现五项包含183例患者的RCT符合纳入荟萃分析的条件。汇总分析表明,与对照组相比,NAC对降低短期死亡率[风险比(RR)=0.73;95%置信区间(CI):0.50-1.07;P=0.10]或30天死亡率(RR=0.72;95%CI:0.44-1.19;P=0.20)没有作用。然而NAC组的重症监护病房(ICU)住院时间缩短了[加权平均差(WMD),-4.56;95%CI:(-7.32至-1.80);P=0.001]。两组之间动脉血氧分压与吸入氧分数之比无显著差异[WMD,54.34;95%CI:(-30.50至139.17);P=0.21]。纳入的患者未观察到严重不良反应。基于目前的荟萃分析,尽管ICU住院时间缩短,但NAC对ARDS的临床益处有限。由于纳入的试验和患者数量较少,需要更多试验为NAC在ARDS中的疗效提供充分证据。